REGN Regeneron Pharmaceuticals Inc
Company Analysis
Latest News
Regeneron Upgraded to 'Buy' by UBS on Strong Dupixent Outlook
UBS Group upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from "Neutral" to "Buy" on October 15, 2026. The firm also raised its price target from $660 to...
Alvotech, Advanz Seek European Approval for High-Dose Eylea Biosimilar
Alvotech and Advanz Pharma announced the submission of a European regulatory application for a biosimilar version of Regeneron’s high-dose Eylea (8 mg). It is...
Regeneron Reports Zero New FOP Lesions With Pasatru, Weeks 56–84
Regeneron announced positive 84-week data from the Phase 3 OPTIMA trial extension for Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans...
Regeneron to Present 3.5-Year Libtayo Survival Data at ESMO 2026
Regeneron Pharmaceuticals will present new late-breaking clinical data at the European Society for Medical Oncology (ESMO) 2026 Congress. The presentations...
Regeneron Reports 73% Response in 11-Patient Ovarian Cancer Trial
Regeneron reported positive initial results from a Phase 1/2 trial of investigational drug ubamatamab in patients with recurrent low-grade serous ovarian...
Regeneron Grants Long-Term Performance-Based Equity Awards to CEO and CSO
Regeneron Pharmaceuticals announced a one-time, 100% performance-based equity award for its CEO, Leonard S. Schleifer, and CSO, George D. Yancopoulos,...
Kodiak's Eye-Drug Triumph Hammers Regeneron — But Can Dupixent Carry The Weight Alone?
Shares of Regeneron plunged 13% to $659.42 as investors digested a new competitive threat to the company's already-shrinking eye-drug empire. The catalyst:...
🔴 Regeneron Pharmaceuticals is trading 13.04% down in after-hours trading following positive Phase 3 DAYBREAK results from rival Kodiak Sciences
Regeneron Pharmaceuticals is trading 13.04% down at $659.42 after-hours. - Rival Kodiak Sciences reported positive Phase 3 DAYBREAK results for its eye-drug...
Regeneron Shares Drop 4.54% Ahead of October 30 Earnings
Regeneron Pharmaceuticals (REGN) shares fell 4.54% on Monday, reaching a low of $752.25. Investors grew cautious ahead of the company’s third-quarter earnings...
🔴 Regeneron Pharmaceuticals is trading 4.05% down amid higher oil prices and rising Treasury yields
Regeneron Pharmaceuticals is trading at $756.09, down 4.05%, amid broader risk-off pressure from renewed geopolitical tension, higher oil prices and rising...
🔴 Regeneron Pharmaceuticals is trading 5% down in pre-market — no confirmed catalyst identified
Regeneron Pharmaceuticals is trading 5% down at $755.51 after falling from the September 21 close of $798.17, with no confirmed September 22 company...
🟢 Regeneron Pharmaceuticals is trading 7.22% up in after-hours trading — no verified company-specific catalyst found
Regeneron Pharmaceuticals is trading 7.22% up in after-hours trading at $841.51, after closing at $784.85 on September 18, 2026; no verified company-specific...
Regeneron Sued Over Melanoma Trial, Alleging Misleading Disclosures
Regeneron Pharmaceuticals faces a securities class-action lawsuit regarding its Phase III trial for a melanoma treatment combining fianlimab and Libtayo. The...
🟢 Regeneron Pharmaceuticals is trading 4.8% up in pre-market with no clear company-specific catalyst
Regeneron Pharmaceuticals is trading 4.8% up at $831.71, with no clear company-specific catalyst identified. - It closed at $793.26 on September 10, 2026. -...
🔴 Regeneron Pharmaceuticals is trading 4.49% down in pre-market as no clear company-specific catalyst was identified
Regeneron Pharmaceuticals is trading 4.49% down at $791.27 in pre-market, with no clear August 25, 2026 company-specific catalyst identified. - The FDA...
DCF Advisers LLC Takes a New $5.77 Million Position in Regeneron
DCF Advisers LLC purchased 9,250 shares of Regeneron Pharmaceuticals, valued at approximately $5.77 million. This stake represents 1.0% of DCF Advisers'...
Regeneron Wins FDA Approval for Pasatru, Reducing Bone Lesions by 90%
The FDA approved Regeneron Pharmaceuticals’ Pasatru (garetosmab-grts) for adults with Fibrodysplasia Ossificans Progressiva (FOP). FOP is an ultra-rare genetic...
🟢 Regeneron Pharmaceuticals rises 4.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Regeneron sued by investors, alleging misleading Fianlimab melanoma trial data
Multiple law firms filed a securities class-action lawsuit against Regeneron Pharmaceuticals on August 10, 2026. The lawsuit represents investors who...
🔴 Regeneron Pharmaceuticals is trading 4.4% down today with no clear company-specific catalyst found
Regeneron Pharmaceuticals is trading at $725.98 (-4.38%) in pre-market sessions after closing at $759.24 on August 3, 2026, with no immediate news explaining...